Lv74
4970 积分 2023-04-18 加入
Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia
9天前
已完结
Cutaneous Toxicities of Small Molecules in Targeted Cancer Therapy Part I – Mechanisms of Toxicity
9天前
已完结
Advances and resistance adaptation in BTK-targeted therapy for B-cell malignancies
9天前
已完结
BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies
9天前
已完结
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
9天前
已完结
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches
9天前
已完结
Diagnosis and Treatment of Chronic Lymphocytic Leukemia
9天前
已完结
Chronic lymphocytic leukaemia
9天前
已完结
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
9天前
已完结
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
9天前
已完结
皖公网安备34019202002308
